Search Results
Your search for ,aLl matches 18302 pages
Showing 12101 - 12150COA Releases 2016 Community Oncology Practice Impact Report
On October 4, the Community Oncology Alliance (COA) released the 2016 Community Oncology Practice Impact Report, which tracks the changing landscape of cancer care in the United States. It documents a 121% increase in community cancer clinic closings and a 172% increase in consolidation into...
Safety of Extreme Hypofractionation Reassuring in Intermediate-Risk Prostate Cancer
Giving patients larger fractions of radiation over shorter periods (ie, hypofractionation) is gaining ground in several types of cancers. This approach is attractive for patients’ convenience, shortening treatment and travel times, and also for resource utilization. Several studies have shown that ...
Modification of Dosage Regimen for Nivolumab in Renal Cell Carcinoma, Melanoma, and NSCLC
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On September 13, 2016, the U.S. Food and Drug Administration...
Investigational Immunotherapy Appears Safe and Somewhat Active in Advanced Melanoma
The investigational immunotherapeutic IMC-20D7S was found to be well tolerated and somewhat active in patients with advanced melanoma, including one complete response, according to the results of a phase I/Ib trial reported by Khalil et al in Clinical Cancer Research. IMD-20D7S is a...
Retrospective Studies Confirm Survival Benefit of Stereotactic Body Radiotherapy in Early-Stage NSCLC
Stereotactic body radiation therapy is becoming more widely adopted for the treatment of early-stage non–small cell lung cancer (NSCLC). Along with its increasing uptake, survival has significantly increased over the past decade, according to two large retrospective studies presented at the 58th...
Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma in Situ
A clinical practice guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ has been jointly developed by the Society of Surgical Oncology (SSO), the American Society for Radiation Oncology (ASTRO), and ASCO.1-3 The recommendations were...
‘Dear Presidential Candidates’: A Letter From an Oncologist
Dear Presidential Candidates: Wouldn’t it be great if history’s Alexander the Great was actually Dr. Alexander Fleming, the doctor-scientist who saved millions of lives by discovering penicillin, rather than the other Alexander, who conquered and killed thousands of innocent people? Wouldn’t it be...
Study Shows Strong Evidence Supporting Radiation Boost to Tumor Bed in Ductal Carcinoma in Situ
A radiation boost to the local tumor bed following treatment with breast-conserving therapy (ie, local excision followed by whole-breast radiation therapy) improves local control for patients with ductal carcinoma in situ, according to a study of pooled data from 10 academic centers,1 presented at...
Study Finds PFS Benefit, but No Overall Survival Benefit, for Ipilimumab in Metastatic Castration-Resistant Prostate Cancer
Ipilimumab (Yervoy) was associated with prolonged progression-free survival—but not overall survival—compared with placebo in men with asymptomatic or minimally symptomatic chemotherapy-naive metastatic castration-resistant prostate cancer without visceral metastases, according to a...
Adding Pembrolizumab to Carboplatin/Pemetrexed Seems to Improve Response in Advanced Nonsquamous NSCLC
As reported by Langer et al in The Lancet Oncology, findings in a phase II cohort of the multicohort KEYNOTE-021 study showed that the addition of first-line pembrolizumab (Keytruda) to carboplatin/pemetrexed (Alimta) significantly increased the response rate in patients with advanced nonsquamous...
Does Adding Daratumumab to Lenalidomide/Dexamethasone Improve Outcomes in Previously Treated Multiple Myeloma?
The addition of the CD38-targeted antibody daratumumab (Darzalex) to lenalidomide (Revlimid)/dexamethasone improved progression-free survival in patients with previously treated multiple myeloma, according to the results of the phase III POLLUX trial reported by Dimopoulos et al in The New England...
Expert Point of View: Stephen R.D. Johnston, MD
“These results apply to about two-thirds of women with advanced breast cancer, ie, those with hormone receptor–positive metastatic breast cancer,” noted the formal discussant of this paper, Stephen R.D. Johnston, MD, of the Royal Marsden Hospital, London. “At present with first-line endocrine...
Combination of Ribociclib and Letrozole Improved Progression-Free Survival in Hormone Receptor–Positive Advanced Breast Cancer
The combination of the selective CDK4/6 inhibitor ribociclib plus letrozole significantly improved progression-free survival in hormone receptor–positive advanced breast cancer. When ribociclib was added to letrozole, progression-free survival improved by 44% compared with letrozole alone,...
ESMO 2016: Nivolumab Maintains Function and Reduces Symptoms in Relapsed Metastatic Head and Neck Cancer
Nivolumab (Opdivo) maintains function and reduces symptoms in treatment of relapsed metastatic head and neck cancer, according to results from the CheckMate 141 trial presented by Harrington et al at the 2016 European Society for Medical Oncology (ESMO) Congress in Copenhagen, Denmark (Abstract...
Impact of Severe Fatigue on Treatment Outcome and Social Reintegration in Hodgkin Lymphoma
Severe cancer-related fatigue was associated with poorer clinical outcomes in patients receiving standard therapies for Hodgkin lymphoma and poorer social reintegration, according to an analysis of data from German Hodgkin Study Group trials reported in the Journal of Clinical Oncology by Behringer ...
Genetic Markers Associated With Pathologic Complete Response to Neoadjuvant Therapy Identified in HER2-Positive Breast Cancer
In an analysis reported in JAMA Oncology, Fumagalli et al identified genetic markers associated with pathologic complete response among women with early-stage HER2-positive breast cancer receiving neoadjuvant therapy in the phase III NeoALTTO trial. Study Details In the NeoALTTO trial, 455...
First-Line Pembrolizumab Improves Survival vs Platinum-Based Chemotherapy in Advanced PD-L1–Positive NSCLC
Pembrolizumab (Keytruda) significantly improved progression-free and overall survival vs platinum-based chemotherapy in patients with previously untreated advanced non–small cell lung cancer (NSCLC) with ≥ 50% PD-L1 (programmed cell death ligand 1) expression and no sensitizing EGFR...
HHS Finalizes MACRA Rule, ASCO Applauds Focus on High-Quality Patient-Centered Care
Today, the Department of Health & Human Services (HHS) finalized a landmark new payment system for Medicare clinicians that will continue the Administration’s progress in reforming how the health-care system pays for care. The Medicare Access and CHIP Reauthorization Act of ...
ESMO 2016: Researchers Identify Factors Associated With End-of-Life Chemotherapy Use
The rates of administering chemotherapy to patients with solid cancers within a month of succumbing to their disease remain high, which calls for a paradigm shift to consider initiating palliative care at an earlier stage and formulating clear guidelines for end-of-life care, according to findings...
ESMO 2016: Antitumor Activity Demonstrated With Lurbinectedin in Patients With Metastatic Breast Cancer and BRCA Mutations
Lurbinectedin showed promising clinical benefit in pretreated patients with metastatic breast cancer and BRCA1 or BRCA2 mutations, including patients previously treated with platinum, according to phase II trial results presented by Balmaña et al at the 2016 European Society for Medical...
Study Finds Niraparib Maintenance Improves Progression-Free Survival in Platinum-Sensitive Recurrent Ovarian Cancer
In a phase III trial reported at the recent European Society for Medical Oncology Congress and in The New England Journal of Medicine by Mirza et al, maintenance therapy with the PARP (poly ADP ribose polymerase) 1/2 inhibitor niraparib significantly prolonged progression-free survival vs placebo...
ESMO 2016: Nintedanib Improves Progression-Free Survival but Not Overall Survival in Metastatic Colorectal Cancer
Nintedanib (Ofev) improves progression-free survival but not overall survival in patients with metastatic colorectal cancer who are not responding to standard therapies, according to the results of the phase III LUME-colon 1 trial presented by Van Cutsem et al at the 2016 European Society of...
First-Line Ribociclib Prolongs Progression-Free Survival in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
In a phase III trial reported at the recent European Society for Medical Oncology Congress and in The New England Journal of Medicine by Hortobagyi et al, first-line treatment with ribociclib, a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), resulted in significantly longer...
ESMO 2016: Significant Survival Gains From Neoadjuvant Chemotherapy for High-Risk Soft-Tissue Sarcoma
Neoadjuvant chemotherapy with an anthracycline plus ifosfamide was associated with significant survival gains in patients with soft-tissue sarcoma of the trunk or extremities who are at high-risk of recurrence, in an interim analysis that led to the early discontinuation of a trial presented by...
ESMO 2016: Pembrolizumab a New Option for First-Line Treatment of Patients With Advanced Lung Cancer and High PD-L1 Expression
Pembrolizumab (Keytruda) is set to become a new option for first-line treatment of patients with advanced lung cancer and high programmed cell death ligand 1 (PD-L1) expression, according to the results of the phase III KEYNOTE-024 trial presented by Reck et al at the 2016 European Society for ...
ESMO 2016: Niraparib Significantly Improves Outcomes in Platinum-Sensitive Recurrent Ovarian Cancer
The PARP inhibitor niraparib significantly improves the outcome of platinum-sensitive recurrent ovarian cancer, according to full data from the ENGOT-OV16/NOVA trial presented by Mirza et al at the 2016 European Society for Medical Oncology (ESMO) Congress in Copenhagen (Abstract LBA3_PR), and...
ESMO 2016: Ipilimumab as Adjuvant Therapy Improves Overall Survival in High-Risk Stage III Melanoma
Ipilimumab (Yervoy) as adjuvant therapy significantly improves overall survival in patients with high-risk stage III melanoma, according to the European Organisation for Research and Treatment of Cancer (EORTC) 18071 phase III trial results presented by Eggermont et al at the European Society for...
Lack of Androgen Receptor Protein May Contribute to Racial Disparities in Triple-Negative Breast Cancer Outcomes
Triple-negative breast cancer in African American women is much more likely to lack the androgen receptor protein compared with triple-negative breast cancer in European American women, and this may contribute to the racial disparity in survival outcomes among these two populations, according to a...
Is Second-Line Ramucirumab of Benefit in Advanced Hepatocellular Carcinoma?
In an exploratory analysis of the REACH trial in advanced hepatocellular carcinoma reported in JAMA Oncology, Zhu et al found a borderline survival benefit of second-line ramucirumab (Cyramza) vs placebo among patients with a Child-Pugh score of 5 and a significant benefit among patients with a...
Good CNS Response to Alectinib Reported in Previously Treated ALK-Positive Non–Small Cell Lung Cancer
In a pooled analysis reported in the Journal of Clinical Oncology, Gadgeel et al found that alectinib (Alecensa) was associated with good central nervous system (CNS) response in patients with ALK-positive non–small cell lung cancer (NSCLC) previously treated with crizotinib (Xalkori). Study ...
African American Cancer Survivors More Likely to Experience Lasting Debt Related to Cancer and Its Treatment
African American cancer survivors are more likely than whites to experience lasting debt or forgo necessary medical care as they struggle with the financial burden of cancer, while whites are somewhat more likely to use existing assets to pay for their cancer care, according to a study (C13)...
Modified Staging System for Pancreatic Neuroendocrine Tumors
As reported in the Journal of Clinical Oncology, Luo et al found that a modified staging classification based on the European Neuroendocrine Tumor Society (ENETS) and the American Joint Committee on Cancer (AJCC) staging classifications may improve distinction among risk groups in pancreatic...
Extended Active Surveillance Prior to Systemic Therapy May Be Safe in Some Patients With Metastatic Renal Cell Carcinoma
In a phase II trial reported in The Lancet Oncology, Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, and colleagues found that some patients with metastatic renal cell carcinoma can safely undergo active surveillance for an extended duration prior to initiation of systemic...
Bevacizumab/Capecitabine vs Bevacizumab/Paclitaxel in HER2-Negative Breast Cancer
As reported in The Lancet Oncology by Christoph Zielinski, MD, of the Medical University of Vienna and the Central European Cooperative Oncology Group, and colleagues, the final results of the phase III TURANDOT trial showed that overall survival with first-line bevacizumab (Avastin)/capecitabine...
Tailoring Breast Cancer Screening for Older Women by Breast Density and Risk
A collaborative modeling study evaluating outcomes for various screening intervals for women over the age of 50 based on breast density and risk for breast cancer has found that average-risk women with low breast density undergoing triennial screening and higher-risk women with high breast density...
HHS Takes Steps to Provide More Information on Clinical Trials to the Public
To make information about clinical trials widely available to the public, the U.S. Department of Health and Human Services (HHS) issued a final rule on September 19 that specifies requirements for registering certain clinical trials and submitting summary results information to ClinicalTrials.gov....
The FDA Urges Physicians and Patients to Forgo Ovarian Cancer Screening Tests
In a Safety Communication directed at women and physicians, the U.S. Food and Drug Administration (FDA) alerted women “about the risks associated with the use of tests being marketed as ovarian cancer screening tests” and recommended “against using currently offered tests to screen for ovarian...
The Medical Profession Has to Become Culturally Sensitive to the Needs of LGBT Cancer Survivors
Despite my breast cancer diagnosis 4 years ago, I feel really lucky. My cancer was detected relatively early, stage IIB, during a routine mammogram screening—a test that many of my lesbian friends skip because they don’t want to deal with a medical system steeped in a heterosexual culture that is...
Friendship
Mr. C is almost 90 now, but every summer the boxes of squash, pumpkins, tomatoes, and other vegetables from his truck farm still arrive like clockwork at our door. The cancer that required treatment 17 years ago has never recurred. He’s now struggling with a new problem, recovering from a broken...
ASCO Recommends ‘Quick Wins’ for National Cancer Moonshot
Last month, ASCO recommended to Vice President Joe Biden several immediate and practical actions the Cancer Moonshot Initiative could take during the remainder of his term in the White House—steps that could make a lasting impact in the effort to discover new cancer treatments. ASCO’s...
ASCO Supports Recent Tobacco Legislation
On August 8, the U.S. Food and Drug Administration’s (FDA) rule giving the agency the authority to regulate e-cigarettes, cigars, hookahs, and pipe tobacco took effect. In May, ASCO applauded the FDA for exercising its congressionally mandated authority to regulate e-cigarettes as a crucial step in ...
Advanced Cancer Care Planning Booklet for Your Patients and Caregivers
The ASCO Answers Advanced Cancer Care Planning booklet contains comprehensive information about how patients can communicate directly and honestly about advanced cancer and end-of-life care with friends, family, children, and the health-care team. Featured content includes: Thorough descriptions...
Are You Ready for MACRA? ASCO Offers Educational Resources and Events to Help Practices Prepare
There are only a few months to go before program changes go into effect under the Medicare Access and CHIP Reauthorization Act (MACRA) on January 1, 2017. MACRA was enacted more than a year ago to replace the Sustainable Growth Rate formula for updates to the Medicare physician fee schedule, and it ...
ASCO International Course Helps Ethiopia Realize Its Goal of Improving Cancer Care
Ethiopia, similar to other African countries, has a significant shortage of physicians. Currently, there are 0.3 physicians for every 100,000 people, a rate that is substantially lower than the 2 physicians per 100,000 people found in the rest of Africa. This year, the First Lady of Ethiopia,...
CCF Conquerors Circle Recognizes Donors
The Conquerors Circle is the Conquer Cancer Foundation’s (CCF) first-ever donor appreciation society. Donors who contribute $1,000 annually are members of the Conquerors Circle. In appreciation for their generous and loyal support of CCF, Conquerors Circle members receive exclusive benefits based...
ASCO President-Elect Bruce E. Johnson, MD, FASCO, Reflects on Volunteer Service, Plans for Presidential Term
Bruce E. Johnson, MD, FASCO, began his term as ASCO President-Elect in June 2016 and will serve as 2017–2018 President. A thoracic cancer specialist, Dr. Johnson is Chief Clinical Research Officer and institute physician at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical...
Multiple Myeloma Research Foundation to Donate Data to NCI’s Genomic Data Commons
The National Cancer Institute (NCI) recently announced a collaboration with the Multiple Myeloma Research Foundation to incorporate the Foundation’s wealth of genomic and clinical data about the disease into the NCI Genomic Data Commons. NCI’s Genomic Data Commons is a publicly available database...
Susan M. O’Brien, MD, Embraces the Challenge of Balancing Patient Care With Clinical Trial Investigation
Susan M. O’Brien, MD, one of the nation’s foremost leukemia experts, told The ASCO Post that she wanted to become a doctor since her earliest memories. “The idea of being able to help sick people always appealed to me,” said Dr. O’Brien, who was born in Manhattan but spent her formative years in...
Particular HPV Strain Linked to Improved Prognosis for Oropharyngeal Cancer
When it comes to cancer-causing viruses like human papillomavirus (HPV), researchers are continuing to find that infection with one strain may be better than another. In an analysis of survival data for patients with oropharyngeal cancer, researchers from the University of North Carolina (UNC)...
Temozolomide vs Radiotherapy in High-Risk Low-Grade Glioma
In the phase III EORTC (European Organisation for Research and Treatment) 22033-26033 intergroup trial reported in The Lancet Oncology, Baumert et al found no progression-free survival difference between temozolomide chemotherapy and radiotherapy alone in patients with high-risk low-grade glioma....
